Company registration number 09823188 (England and Wales)
HAQUE MEDICALS LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2025
PAGES FOR FILING WITH REGISTRAR
HAQUE MEDICALS LIMITED
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 3
HAQUE MEDICALS LIMITED
BALANCE SHEET
AS AT
31 OCTOBER 2025
31 October 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Investment property
3
172,829
172,829
Current assets
Debtors
4
50,032
50,032
Cash at bank and in hand
66,153
60,119
116,185
110,151
Creditors: amounts falling due within one year
5
(56,319)
(52,904)
Net current assets
59,866
57,247
Total assets less current liabilities
232,695
230,076
Creditors: amounts falling due after more than one year
6
(64,723)
(71,516)
Net assets
167,972
158,560
Capital and reserves
Called up share capital
200
200
Profit and loss reserves
167,772
158,360
Total equity
167,972
158,560

For the financial year ended 31 October 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

T he members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved and signed by the director and authorised for issue on 19 July 2026
Dr A Hussain
Director
Company registration number 09823188 (England and Wales)
HAQUE MEDICALS LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2025
- 2 -
1
Accounting policies
Company information

Haque Medicals Limited is a private company limited by shares incorporated in England and Wales. The registered office is 19 Murray Street, Llanelli, SA15 1AQ.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2
Investment property

Investment property, which is property held to earn rentals and/or for capital appreciation, is initially recognised at cost, which includes the purchase cost and any directly attributable expenditure. Subsequently it is measured at fair value a t the reporting end date. Changes in fair value are recognised in profit or loss.

1.3
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
1
1
HAQUE MEDICALS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
- 3 -
3
Investment property
2025
£
Fair value
At 1 November 2024 and 31 October 2025
172,829

The director is of the opinion that this is its market value at 31st October 2025.

4
Debtors
2025
2024
Amounts falling due within one year:
£
£
Other debtors
50,032
50,032
5
Creditors: amounts falling due within one year
2025
2024
£
£
Bank loans
6,046
5,298
Corporation tax
2,208
2,370
Other creditors
48,065
45,236
56,319
52,904

The company's bank loan is secured by a charge over the company's freehold property and a fixed and floating charge over the company's assets,

6
Creditors: amounts falling due after more than one year
2025
2024
£
£
Bank loans and overdrafts
64,723
71,516

The company's bank loan is secured by a charge over the company's freehold property and a fixed and floating charge over the company's assets.

Included within creditors: amounts falling due after more than one year is an amount of £40,540 (2024 £50,322) in respect of liabilities payable or repayable by instalments which fall due for payment after more than five years from the reporting date.

The loan is repayable by 180 monthly instalments and interest is charged at 3.15% per annum.

7
Related party transactions

The company is owed £50,001 by a trading company owned by a relative of the company's director. The amount advanced is interest free and repayable on demand.

2025-10-31 2024-11-01 false false false 20 July 2026 CCH Software CCH Accounts Production 2026.100 No description of principal activity Dr A Hussain Dr C R Kaniz 09823188 2024-11-01 2025-10-31 09823188 2025-10-31 09823188 2024-10-31 09823188 core:CurrentFinancialInstruments core:WithinOneYear 2025-10-31 09823188 core:CurrentFinancialInstruments core:WithinOneYear 2024-10-31 09823188 core:Non-currentFinancialInstruments core:AfterOneYear 2025-10-31 09823188 core:Non-currentFinancialInstruments core:AfterOneYear 2024-10-31 09823188 core:CurrentFinancialInstruments 2025-10-31 09823188 core:CurrentFinancialInstruments 2024-10-31 09823188 core:ShareCapital 2025-10-31 09823188 core:ShareCapital 2024-10-31 09823188 core:RetainedEarningsAccumulatedLosses 2025-10-31 09823188 core:RetainedEarningsAccumulatedLosses 2024-10-31 09823188 bus:Director1 2024-11-01 2025-10-31 09823188 2023-11-01 2024-10-31 09823188 2024-10-31 09823188 core:Non-currentFinancialInstruments 2025-10-31 09823188 core:Non-currentFinancialInstruments 2024-10-31 09823188 bus:PrivateLimitedCompanyLtd 2024-11-01 2025-10-31 09823188 bus:SmallCompaniesRegimeForAccounts 2024-11-01 2025-10-31 09823188 bus:FRS102 2024-11-01 2025-10-31 09823188 bus:AuditExemptWithAccountantsReport 2024-11-01 2025-10-31 09823188 bus:CompanySecretary1 2024-11-01 2025-10-31 09823188 bus:FullAccounts 2024-11-01 2025-10-31 xbrli:pure xbrli:shares iso4217:GBP